Oxford Biomedica (LON:OXB) Stock Price Breaks Below 200 Day Moving Average - Time to Sell?

Key Points

• Oxford Biomedica shares fell below their 200-day moving average, trading as low as GBX 513 versus the GBX 567.15 average, and last changing hands at GBX 521.
• Analysts remain moderately optimistic: three rate the stock Buy and one Hold, producing a consensus “Moderate Buy” rating and a GBX 613.32 price target.
• The company reported a quarterly loss of GBX 30.39 per share, with a negative 23.23% net margin and 54.51% return on equity; however, insider Roch Doliveux bought 20,250 shares worth approximately £102,263.

Oxford Biomedica plc (LON:OXB - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of GBX 567.15 and traded as low as GBX 513. Oxford Biomedica shares last traded at GBX 521, with a volume of 147,276 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on OXB shares. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 595 price target on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Royal Bank Of Canada restated an "outperform" rating and issued a GBX 900 price objective on shares of Oxford Biomedica in a report on Tuesday, September 1st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of GBX 613.32.

Oxford Biomedica Stock Performance

The business has a fifty day simple moving average of GBX 495.77 and a two-hundred day simple moving average of GBX 567.15. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67. The company has a market cap of £630.66 million, a PE ratio of -16.30 and a beta of 1.09.

Oxford Biomedica (LON:OXB - Get Free Report) last announced its quarterly earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. Research analysts anticipate that Oxford Biomedica plc will post -31.08 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Roch Doliveux purchased 20,250 shares of the firm's stock in a transaction on Wednesday, September 23rd. The stock was acquired at an average cost of GBX 505 per share, with a total value of £102,262.50. Corporate insiders own 25.83% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.